GlassScriptPhysician profile
Sundeep Mandava
NPI 1497117634
$1,978.92
in general payments reported to CMS, 2019-2025
13 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.62 · 2023: $573 · 2024: $789 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $756.81 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $581.38 | 2022-2025 | |
| Neurelis, INC. | $274.72 | 2023-2025 | Valtoco |
| Tris Pharma INC | $81.95 | 2025 | Onyda Xr, Dyanavel Xr |
| Aucta Pharmaceuticals, INC. | $73.51 | 2024-2025 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $32.65 | 2023-2024 | Zonisade, Eprontia |
| Sumitomo Pharma America, INC. | $31.33 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $30.01 | 2025 | Qelbree |
| Microtransponder, INC. | $25.82 | 2023 | |
| Sk Life Science, INC. | $25.60 | 2024 | |
| Immedica Pharma US, INC. | $25.54 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.67 | 2025 | Ajovy |
| Cranial Technologies, INC | $15.93 | 2025 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sundeep Mandava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.